Chemists agree that a sustainable future requires reducing reliance on precious metals such as palladium and rhodium. Many of them hold up earth-abundant first-row transition metals as green alternatives to the precious metals used to catalyze cross couplings and other important organic reactions needed to synthesize drug molecules. First-row metals are less costly and less carbon intensive to refine, and they can do a lot of useful chemistry. But making catalytic reactions more sustainable requires thinking about more than just swapping out precious-metal catalysts for earth-abundant ones. On a summer day about 20 years ago, Paul Chirik returned to his laboratory after a conference with a question on his mind: Why do chemists use expensive rhodium to do hydrogenation reactions? Why don't they use something more available, such as iron? Chemists are rightfully proud of the transition-metal catalysts they developed to enable certain organic transformations. For example, rhodium catalyzes asymmetric
No takes yet. Share an insight, caveat, or question.
Brianna Barbu (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: